Summary
Stiripentol (STP) is a new antiepileptic compound made by Biocodex. It recently proved to increase the GABAergic transmissionin vitro in an experimental model of immature rat. Clinical studies were based on the fact that STP also acts as an inhibitor of CYP3A4, CYP1A2, and CYP2C19in vivo in epileptic patients. Whereas the studies in adult patients were disappointing, the trials conducted in pediatric populations demonstrated a specific efficacy of STP in severe myoclonic epilepsy in infancy, Dravet syndrome, when combined with valproate and clobazam. Based on these results, STP was granted orphan drug status in the European Union for the treatment of Dravet syndrome. The French experience in compassionate use suggests that STP might also be of benefit when combined with carbamazepine in pediatric patients with pharmacoresistant partial epilepsy. The interactions of STP with a large number of drugs need to be carefully taken into account, with doses of the combined antiepileptic drugs adjusted to improve the tolerability of the therapeutic association.
Key Words: Stiripentol, antiepileptic drugs, childhood epilepsy, severe myoclonic epilepsy, cytochrome P450 interactions
References
- 1.Poisson M, Huguet F, Savattier A, Bakri-Logeais F, Narcisse G. A new type of anticonvulsant, stiripentol: pharmacological profile and neurochemical study. Arzneimittelforschung. 1984;34:199–204. [PubMed] [Google Scholar]
- 2.Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA-receptor channels. Epilepsia. 2006;47:704–716. doi: 10.1111/j.1528-1167.2006.00497.x. [DOI] [PubMed] [Google Scholar]
- 3.Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62:490–504. doi: 10.1016/S0009-9236(97)90044-8. [DOI] [PubMed] [Google Scholar]
- 4.Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356:1638–1642. doi: 10.1016/S0140-6736(00)03157-3. [DOI] [PubMed] [Google Scholar]
- 5.Levy RH, Loiseau P, Guyot M, Blehaut HM, Tor J, Moreland TA. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther. 1984;36:661–669. doi: 10.1038/clpt.1984.237. [DOI] [PubMed] [Google Scholar]
- 6.Tran A, Vauzelle-Kervroedan F, Rey E, et al. Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Eur J Clin Pharmacol. 1996;50:497–500. doi: 10.1007/s002280050147. [DOI] [PubMed] [Google Scholar]
- 7.Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34:608–611. doi: 10.1124/dmd.105.007237. [DOI] [PubMed] [Google Scholar]
- 8.Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40:1618–1626. doi: 10.1111/j.1528-1157.1999.tb02048.x. [DOI] [PubMed] [Google Scholar]
- 9.Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology. 2000;54:2237–2244. doi: 10.1212/wnl.54.12.2237. [DOI] [PubMed] [Google Scholar]
- 10.Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology. 1999;52:1882–1887. doi: 10.1212/wnl.52.9.1882. [DOI] [PubMed] [Google Scholar]
- 11.Chiron C, Tonnelier S, Rey E, et al. Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. J Child Neurol. 2006;21:496–502. doi: 10.1177/08830738060210062101. [DOI] [PubMed] [Google Scholar]
- 12.Thanh TN, Chiron C, Dellatolas G, et al. Efficacité et tolérance à long terme du stiripentol dans le traitement de l’épilepsie myoclonique sévère du nourrisson (syndrome de Dravet) Arch Pediatr. 2002;9:1120–1127. doi: 10.1016/S0929-693X(02)00090-8. [DOI] [PubMed] [Google Scholar]
- 13.Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. 1998;29:147–154. doi: 10.1016/S0920-1211(97)00080-6. [DOI] [PubMed] [Google Scholar]
- 14.Nieto-Barrera M, Candau R, Nieto-Jimenez M, Correa A, del Portal LR. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000;9:590–594. doi: 10.1053/seiz.2000.0466. [DOI] [PubMed] [Google Scholar]
- 15.Ceulemans B, Boel M, Claes L, et al. Severe myoclonic epilepsy in infancy: toward an optimal treatment. J Child Neurol. 2004;19:516–521. doi: 10.1177/08830738040190070701. [DOI] [PubMed] [Google Scholar]
- 16.Coppola G, Capovilla G, Montagnini A, et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. 2002;49:45–48. doi: 10.1016/S0920-1211(02)00010-4. [DOI] [PubMed] [Google Scholar]